Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation
This study will compare the incidence of a two-part composite endpoint consisting of de novo donor specific antibody formation or a designation of "immune activation " on peripheral blood molecular profiling in patients maintained on twice daily, immediate-release tacrolimus versus those maintained on Astagraf XL in the first two years post-transplant.
Location: CPMC (San Francisco)
Please contact ClinicalResearch@sutterhealth.org about Study Astellas Astound.
View study details on ClinicalTrials.gov
Subjects, 18 to 65 years old, who are recipients of a de novo kidney from a living or deceased donor.
June 01, 2018